Results from the phase 3 CREDO-1 trial show that treatment with olokizumab over a 24-week period was associated with significant improvements in the signs, symptoms, and physical function of rheumatoid arthritis (RA) as well as in patient-reported outcomes (PROs) in patients with moderate-to-severe RA who previously failed methotrexate therapy [1,2].
Prof. Rumen Stoilov (University Hospital St. Ivan Rilski, Bulgaria) presented the randomised, placebo-controlled, multicentre, phase 3 CREDO-1 trial that evaluated the efficacy and safety of olokizumab, a new humanised monoclonal antibody targeting interleukin(IL)-6 [3,4]. The trial aimed to evaluate the safety and efficacy of olokizumab 64 mg administered subcutaneously every 2 weeks and 64 mg subcutaneously every 4 weeks versus placebo in the treatment of moderate-to-severe active RA despite treatment with methotrexate. Participants (n=428) receiv...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Low DAS at 4 months predicts sustained DMARD-free remission Next Article
New nanoparticle promising future agent in RA »
Table of Contents: EULAR 2020
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.